2005
Therapeutic Strategies for Combined-Modality Therapy of Locally Advanced-Stage Non–Small-Cell Lung Cancer: Rationale for Consolidation Docetaxel Therapy
Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN, Mack P, Gumerlock PH, Crowley JJ. Therapeutic Strategies for Combined-Modality Therapy of Locally Advanced-Stage Non–Small-Cell Lung Cancer: Rationale for Consolidation Docetaxel Therapy. Clinical Lung Cancer 2005, 7: s93-s97. PMID: 16384543, DOI: 10.3816/clc.2005.s.017.Peer-Reviewed Original ResearchConceptsCell lung cancerRadiation therapyDocetaxel therapyLung cancerChemotherapy/radiation therapyGood performance statusCombined modality therapyThoracic radiation therapyRecent clinical trialsStandard of careCombination of chemotherapyPerformance statusDose scheduleTreatment paradigmClinical trialsTherapeutic strategiesTherapyCancerChemotherapyPatientsTrialsCareLimited-Stage Small-Cell Lung Cancer (Stages I-III): Observations from the National Cancer Data Base
Gaspar LE, Gay EG, Crawford J, Putnam JB, Herbst RS, Bonner JA. Limited-Stage Small-Cell Lung Cancer (Stages I-III): Observations from the National Cancer Data Base. Clinical Lung Cancer 2005, 6: 355-360. PMID: 15943896, DOI: 10.3816/clc.2005.n.015.Peer-Reviewed Original ResearchConceptsLimited stage small cell lung cancerSmall cell lung cancerLS-SCLCChemoradiation therapyStandard treatmentLung cancerRadiation therapySole treatmentSurvival rateConcurrent thoracic radiation therapyNational Cancer Data BaseMultiple-agent chemotherapyTreatment pattern changesPercent of patientsProportion of patientsThoracic radiation therapyUse of chemotherapyUse of chemoradiationAge of patientsGroup of patientsConfidence intervalsYears of agePercentage of womenCombined chemotherapyPatient cohort
2003
O-71 Hyperfractionated and accelerated thoracic radiation therapy (HFXA/TRT) increased survival compared to daily TRT for limited small cell lung cancer (LSCLC) patients treated with concurrent chemotherapy
Komaki R, Glisson B, Allen P, Fossella F, Liao Z, Stevens C, Blumenschein G, Hong W, Herbst R, Pisters K. O-71 Hyperfractionated and accelerated thoracic radiation therapy (HFXA/TRT) increased survival compared to daily TRT for limited small cell lung cancer (LSCLC) patients treated with concurrent chemotherapy. Lung Cancer 2003, 41: s24. DOI: 10.1016/s0169-5002(03)91729-6.Peer-Reviewed Original Research
2002
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results
Komaki R, Lee J, Kaplan B, Allen P, Kelly J, Liao Z, Stevens C, Fossella F, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames H, Hong W, Cox J. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results. Seminars In Radiation Oncology 2002, 12: 46-49. PMID: 11917284, DOI: 10.1053/srao.2002.31363.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerThoracic radiation therapyInoperable stage IICell lung cancerSevere esophagitisArm 2Arm 1Lung cancerDay 1Randomized phase III studyStage IIPhase III studyGy/fractionMedian survival timeLong-term efficacyOral etoposideAcute pneumonitisConcurrent chemoradiotherapyIII studyTumor characteristicsPulmonary toxicityStudy groupRadiation therapyDay 29Survival time